Actinium Pharmaceuticals Showcases ATNM-400's Versatile Anti-Cancer Potential at EANM 2026

Actinium Pharmaceuticals, a leader in targeted radiotherapies, presented groundbreaking preclinical results regarding its investigational drug, ATNM-400, at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM) in Vienna. The findings reveal the remarkable efficacy of ATNM-400 across multiple cancers, specifically non-small cell lung cancer, colorectal cancer, and ovarian cancer.

Unprecedented Efficacy of ATNM-400

The preclinical studies showcased ATNM-400's ability to target HER3, a critical antigen associated with tumor survival and resistance to treatment. This innovative approach employs Actinium-225 to deliver potent alpha-particle radiation directly to HER3-expressing tumor cells. The results provide additional evidence supporting the drug's use as both a mono-therapy and a combinatory treatment with existing therapies.

Lung Cancer Breakthroughs

In the realm of lung cancer, ATNM-400 demonstrated significant activity in various models, including those driven by EGFR, KRAS, and ALK mutations. Notably, in the KRAS G12C-mutant model, the drug achieved an impressive 81% tumor growth inhibition, far surpassing the effectiveness of conventional therapies. When combined with the KRAS-targeted treatment, adagrasib, the growth inhibition escalated to an astounding 105%. These findings underscore the potential of ATNM-400 to enhance the effectiveness of established therapies, presenting a novel opportunity for patients with diverse tumor profiles.

Colorectal Cancer Response

ATNM-400's impact extended into colorectal cancer, where it significantly increased the tumor growth inhibition from standard therapies. In particular, when paired with oxaliplatin and bevacizumab, ATNM-400 culminated in a remarkable 72% tumor growth inhibition—an impressive leap from the 25% observed with standard treatment alone. The dual approach not only improved tumor suppression but also enhanced survival rates, particularly in models exhibiting moderate HER3 expression.

Ovarian Cancer Results

The data regarding ATNM-400’s performance in ovarian cancer was equally compelling. In models resistant to conventional therapy post-bevacizumab failure, ATNM-400 achieved a striking 93% tumor growth inhibition as a single agent, reaffirming its relevance and potential for treating patients with limited current options. Furthermore, even in immunocompetent models, ATNM-400 exhibited the capability to prolong survival, further solidifying its position as a candidate for overcoming treatment resistance.

A Vision for the Future

Sandesh Seth, Chairman and CEO of Actinium, emphasized the significance of these results, asserting that they bolster their belief in ATNM-400’s pan-tumor potential. The comprehensive nature of the findings across various cancers supports the notion that ATNM-400 could be integrated as a vital component in the immuno-oncology landscape.

Dr. Adeela Kamal, Chief Scientific Officer of Actinium, pointed to the unique ability of ATNM-400 to disrupt the tumor-cell survival mechanisms without being contingent on a particular oncogenic driver. The dual-action mechanism presents an innovative path to treat diverse oncology cases, potentially reshaping therapeutic strategies moving forward.

Conclusion

As Actinium Pharmaceuticals continues to push the boundaries of cancer treatment, the results revealed at EANM 2026 signal a promising future for ATNM-400. The ability to improve outcomes across different cancer models could pave the way for a new era in targeted radiotherapy, offering hope to patients who currently face limited treatment options. With ongoing studies, the roadmap for ATNM-400 appears promising, and its journey through clinical application promises to be an exciting development in cancer therapeutics.